Literature analysis of drug-induced autoimmune hepatitis induced by tumor necrosis factor-α inhibitor
- VernacularTitle:肿瘤坏死因子α抑制剂致药物诱导自身免疫性肝炎的文献分析
- Author:
Ling MEI
1
;
Yueyuan WANG
2
;
Houfeng ZHOU
1
;
Shan DU
2
Author Information
1. Dept. of Pharmacy，Chengdu Fifth People’s Hospital，Chengdu 611130，China
2. Sichuan Provincial Key Laboratory of Individualized Drug Therapy，Dept. of Pharmacy，Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital/the Affiliated Hospital of University of Electronic Science and Technology of China，Chengdu 610072，China
- Publication Type:Journal Article
- Keywords:
tumor necrosis factor-α inhibitor;
infliximab
- From:
China Pharmacy
2023;34(24):3030-3035
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the characteristics of drug-induced autoimmune hepatitis （DIAIH） induced by tumor necrosis factor-α inhibitor （TNFi）， and to provide reference for clinical drug treatment. METHODS Retrieved from PubMed， Embase， China Academic Journal full-text Database， VIP and Wanfang database， the case reports of TNFi-induced DIAIH were collected to conduct descriptive analysis. RESULTS A total of 33 case reports involving 44 patients were collected， including 31 females and 13 males， with an average age of （41.14±2.20） years old， mostly aged 30 to 60 years （77.27%）. The primary diseases were Crohn disease （CD）， ulcerative colitis （UC） and rheumatoid arthritis （RA） （68.18%）. Of the 44 patients， 35 were treated with infliximab （IFX）， 7 with adalimumab， and 2 with etanercept. The dosage of 37 patients was within the scope of the instructions， and 31 received other drugs additionally； DIAIH mainly occurred ≤24 weeks after medication （68.18%）； 21 patients （47.73%） had no clinical manifestations； alanine aminotransferase and aspartate aminotransferase were abnormally elevated in all patients； anti-nuclear antibodies were positive in 38 patients. Except for 3 patients who required liver transplantation， all the other patients improved after drug withdrawal and/or symptomatic treatment such as glucocorticoid therapy. CONCLUSIONS TNFi- induced DIAIH is more common in female patients and can occur with conventional doses， with significant differences in occurrence time. However， the intervention measures are basically the same for DIAIH induced by different types of TNFi. Clinical use of TNFi， especially the use of IFX， requires close attention to the clinical manifestations， liver function and autoantibody level， and a detailed evaluation should be conducted to detect DIAIH as soon as possible. If liver function continues to not improve， it is necessary to stop taking medicine as soon as possible and receive symptomatic treatment to avoid developing acute or severe DIAIH or liver failure.
